Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 73 out of 100. Treatments

Topic: Amyloid, tau and blood-test diagnosis

Plain-language summary

Background Epidemiologic evidence suggests that nonsteroidal anti-inflammatory drugs (NSAIDs) delay onset of Alzheimer's dementia (AD), but randomized trials show no benefit from NSAIDs in patients with symptomatic AD. The Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT) randomized 2,528 elderly persons to naproxen or celecoxib versus placebo for 2 years (standard deviation = 11 months) before treatments were terminated. During the treatment interval, 32 cases of AD revealed increased rates in both NSAID-assigned groups. Methods We continued the double-masked ADAPT protocol for 2 additional years to investigate incidence of AD (primary outcome). We then collected cerebrospinal fluid (CSF) from 117 volunteer participants to assess their ratio of CSF tau to Aβ(1-42.) Results Including 40 new events observed during follow-up of 2,071 randomized individuals (92% of participants at treatment cessation), there were 72 AD cases. Overall, NSAID-related harm was no longer evident, but secondary analyses showed that increased risk remained notable in the first 2.5 years of observations, especially in 54 persons enrolled with cognitive impairment--no dementia (CIND). These same analyses showed later reduction in AD incidence among asymptomatic enrollees who were given naproxen. CSF biomarker assays suggested that the latter result reflected reduced Alzheimer-type neurodegeneration. Conclusions These data suggest a revision of the original ADAPT hypothesis that NSAIDs reduce AD risk, as follows: NSAIDs have an adverse effect in later stages of AD pathogenesis, whereas asymptomatic individuals treated with conventional NSAIDs such as naproxen experience reduced AD incidence, but only after 2 to 3 years. Thus, treatment effects differ at various stages of disease. This hypothesis is consistent with data from both trials and epidemiological studies.

What this study adds

Evidence grade: High

This is a trial of 54 participants. During the first two years of this prevention trial, more cases of Alzheimer disease appeared in the groups assigned to naproxen or celecoxib than in the placebo group, and increased risk remained notable in the first 2.5 years of observations. Later analyses suggested reduced incidence among asymptomatic enrollees given naproxen, but these were secondary analyses.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Breitner, J. C., Baker, L. D., Montine, T. J., Meinert, C. L., Lyketsos, C. G., Ashe, K. H., et al. (2011). Extended results of the Alzheimer's disease anti-inflammatory prevention trial. Alzheimer's & dementia : the journal of the Alzheimer's Association. https://doi.org/10.1016/j.jalz.2010.12.014

Vancouver

Breitner JC, Baker LD, Montine TJ, Meinert CL, Lyketsos CG, Ashe KH, et al. Extended results of the Alzheimer's disease anti-inflammatory prevention trial. Alzheimer's & dementia : the journal of the Alzheimer's Association. 2011. doi:10.1016/j.jalz.2010.12.014. PMID: 21784351.

BibTeX

@article{breitner2011-21784351,
  author  = {Breitner, J. C. and Baker, L. D. and Montine, T. J. and Meinert, C. L. and Lyketsos, C. G. and Ashe, K. H. and Brandt, J. and Craft, S. and others},
  title   = {{Extended results of the Alzheimer's disease anti-inflammatory prevention trial}},
  journal = {Alzheimer's \& dementia : the journal of the Alzheimer's Association},
  year    = {2011},
  doi     = {10.1016/j.jalz.2010.12.014},
  pmid    = {21784351},
  url     = {https://doi.org/10.1016/j.jalz.2010.12.014}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.

Key findings

Why it matters

During the first two years of this prevention trial, more cases of Alzheimer disease appeared in the groups assigned to naproxen or celecoxib than in the placebo group, and increased risk remained notable in the first 2.5 years of observations. Later analyses suggested reduced incidence among asymptomatic enrollees given naproxen, but these were secondary analyses.

Study details

How this study scored 73/100
How this study's score is builtJournal tier 9 of 10; Journal's citation record 2 of 4; Study design 11 of 12; Strength of evidence 5 of 5; Peer-review validation 10 of 10; How recent 1 of 5; Sample size 1 of 4; Effect reported 0 of 3; Studied in people 3 of 3; Randomized / blinded 1 of 2; Times cited 6 of 7; Citations per year 3 of 5; Impact for its field and year 4 of 6; Cited by studies here 3 of 6; Still being cited 2 of 4; Senior author's track record 4 of 4; Institution's track record 3 of 3; Multicenter collaboration 3 of 3; Indexed in PubMed 2 of 2; Free to read 0 of 2. Total 73 of 100.73 of 100 points earned27 not earned

Published in a leading specialty journal, and it is a randomized controlled trial. Scored zero for effect reported because the record does not state it.

ComponentPointsWhy
Journal tier 9 / 10 Tier 2 — leading specialty journal (Alzheimer's & dementia : the journal of the Alzheimer's Association)
Journal's citation record 2 / 4 Alzheimer s & Dementia: journal h-index 228 (OpenAlex, 2026-10-29)
Study design 11 / 12 A randomized controlled trial (from PubMed type “Randomized Controlled Trial”)
Strength of evidence 5 / 5 Rated “high” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 1 / 5 2011 — within 20 year(s) of the newest study here
Sample size 1 / 4 54 participants
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 3 / 3 Studied in people (participant count stated)
Randomized / blinded 1 / 2 Randomized (as stated in the record)
Times cited 6 / 7 Cited 329 times (OpenAlex, 2026-10-10)
Citations per year 3 / 5 19.4 citations a year over 17 year(s) since 2011
Impact for its field and year 4 / 6 Cited 19.1× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 3 / 6 Cited by 25 other studies in this library
Still being cited 2 / 4 Cited 23 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 4 / 4 Last-listed author Pierre N. Tariot: h-index 102 (OpenAlex, whole career)
Institution's track record 3 / 3 University of Washington: institution h-index 3,540 (OpenAlex)
Multicenter collaboration 3 / 3 OpenAlex lists 16 institution(s) in 2 countries
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 21784351)
Free to read 0 / 2 Behind a paywall — scores zero
Total 73 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — PubMed Central lists this copy as free to read: the link above (checked 10 Oct 2026).

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 14.

Later studies that cite this one

25 studies in the alzhub library list this one in their references. Showing the 8 highest-scoring.

Related studies in Treatments from nearby years

Also tagged “trial”

783 studies in the library carry the topic tag “trial”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 783 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Treatments

See all studies in Treatments →